# A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

> **NCT05674448** · PHASE2 · TERMINATED · sponsor: **Huahui Health** · enrollment: 9 (actual)

## Conditions studied

- Chronic Hepatitis B and Hepatitis D Co-infection

## Interventions

- **BIOLOGICAL:** HH-003 20mg/kg
- **BIOLOGICAL:** HH-003 3mg/kg

## Key facts

- **NCT ID:** NCT05674448
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-11
- **Primary completion:** 2022-07-25
- **Final completion:** 2023-01-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** During the study, the sponsor adjusted the overall clinical development strategy, decided to terminate the enrollment in advance after discussion with the lead investigator.
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674448, "A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05674448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*